Connor, Clark & Lunn Investment Management Ltd. Cytokinetics Inc Transaction History

Connor, Clark & Lunn Investment Management Ltd.

$18.8 Billion
Q3 2024

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 09, 2024	SELL	$63.75 - $108.06 $5.14 Million - $8.72 Million	-80,702 Reduced 61.85%	49,770 $3.49 Million
Q4 2023 Feb 09, 2024	SELL	$26.88 - $83.49 $1.01 Million - $3.13 Million	-37,505 Reduced 22.33%	130,472 $10.9 Million
Q3 2023 Nov 13, 2023	BUY	$29.46 - $36.61 $1.34 Million - $1.67 Million	45,624 Added 37.29%	167,977 $4.95 Million
Q2 2023 Aug 10, 2023	SELL	$32.62 - $40.75 $1.48 Million - $1.84 Million	-45,229 Reduced 26.99%	122,353 $3.99 Million
Q1 2023 May 09, 2023	BUY	$33.36 - $45.71 $191,019 - $261,735	5,726 Added 3.54%	167,582 $5.9 Million
Q4 2022 Feb 10, 2023	BUY	$35.77 - $51.11 $3.49 Million - $4.99 Million	97,572 Added 151.78%	161,856 $7.42 Million
Q3 2022 Nov 10, 2022	SELL	$38.54 - $54.52 $1.14 Million - $1.61 Million	-29,555 Reduced 31.5%	64,284 $3.12 Million
Q2 2022 Aug 05, 2022	BUY	$33.93 - $48.92 $358,775 - $517,280	10,574 Added 12.7%	93,839 $3.69 Million
Q1 2022 May 12, 2022	SELL	$29.74 - $46.0 $441,133 - $682,318	-14,833 Reduced 15.12%	83,265 $3.07 Million
Q4 2021 Feb 10, 2022	BUY	$34.35 - $46.38 $3.37 Million - $4.55 Million	98,098 New	98,098 $4.47 Million

Others Institutions Holding CYTK

# of Institutions

410

Shares Held

125M

Call Options Held

4.6M

Put Options Held

2.43M

Black Rock Inc. New York, NY

14.7M
Shares

$720 Million
0.02% of portfolio
Vanguard Group Inc Valley Forge, PA

11.8M
Shares

$577 Million
0.01% of portfolio
T. Rowe Price Investment Management, Inc. Baltimore, MD

9.69M
Shares

$476 Million
0.31% of portfolio
Wellington Management Group LLP Boston, MA

7.77M
Shares

$382 Million
0.07% of portfolio
State Street Corp Boston, MA

6.46M
Shares

$317 Million
0.01% of portfolio

View Full List

About CYTOKINETICS INC

Ticker CYTK
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 94,144,096
Market Cap $4.62B
Description
Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates i...

More about CYTK

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Connor, Clark & Lunn Investment Management Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Connor, Clark & Lunn Investment Management Ltd. with notifications on news.

Account